National
Cicilline fends off challenger in R.I. primary
Election results yield mixed bag for marriage equality prospects
Gay Rep. David Cicilline defeated his challenger in the Rhode Island Democratic primary on Tuesday. (Blade file photo by Michael Key)
Gay Rep. David Cicilline (D-R.I.) defeated his challenger, businessman Anthony Gemma, to win the Democratic nomination to continue to represent Rhode Island’s 1st congressional district in the U.S. House in Tuesday’s primary.
Local media outlets called the race for Cicilline about an hour after polls closed at 8 p.m. in Rhode Island. With 98 percent of precincts reporting, Cicilline held 61 percent of the vote, compared to the 31 percent claimed by Gemma and 8 percent won by another candidate, Chris Young.
Cicilline faced criticism during the race — even though he’s running in a overwhelmingly “blue” state — as a result of financial difficulties facing the city of Providence, R.I., where Cicilline served as mayor before running for Congress.
A report commissioned by the City Council last year blamed Cicilline’s administration for a lack of transparency and for making a series of moves – like tapping into Providence’s rainy-day fund – without councilors’ approval. The lawmaker apologized in April, saying he should have been more forthright about the financial condition of the city.
Still, Cicilline retained support heading into the primary. The lawmaker was once again endorsed by the Gay & Lesbian Victory Fund. In new campaign ads, former U.S. Rep. Patrick Kennedy, who once held the seat now held by Cicilline, vouched for the out lawmaker’s commitment to public service.
Sexual orientation did come into play during the Democratic primary. According to the Associated Press, Anthony Sionni, an unpaid campaign staffer for the Gemma campaign, compared the openly gay lawmaker on Twitter to convicted child molester and former Penn State coach Jerry Sandusky, saying there’s “nothing wrong with smearing a liar, thief, crook, Sandusky copy cat.” The state Democratic Party had called for Gemma to fire Anthony Sionni, apologize to Cicilline and disavow the message. In response, a Gemma campaign spokesperson reportedly said the tweet was “inappropriate” and Sionni agreed to leave the campaign.
Cicilline was running against a primary opponent who largely self-financed his campaign. According to Federal Election Commission reports, 80 percent of the $315,000 that Gemma raised was from him contributing or lending his money to his own campaign. In comparison, all the $1.7 million that Cicilline raised for his campaign was the result of outside contributions.
But Cicilline isn’t out of the woods in his bid to retain his U.S. House seat. He’s facing a challenge in the general election from Republican Brendan Doherty, a retired high-ranking police officer and former superintendent of Rhode Island’s Department of Public Safety.
According to a poll published by Rhode Island’s WPRI late last month, 52 percent of Gemma supporters said they’d back Doherty in the general election if the Democratic challenger lost the primary. Compared to the $1.7 million that Cicilline has raised, Doherty has $1.1 million in total net receipts. About five percent, or $50,000, of Doherty’s net receipts are from self-financing.
Chuck Wolfe, the Victory Fund’s CEO, said the choice is clear on LGBT issues heading into the general election because Doherty supports the Defense of Marriage Act, an anti-gay law that prohibits federal recognition of same-sex marriage.
“We’re pleased that Rhode Island Democrats have once again chosen David Cicilline to represent them in Congress,” Wolfe said. “Now voters will face a clear choice this November between a persistent champion for LGBT equality, and an opponent who supports the Defense of Marriage Act, which makes life harder for so many American families.”
The Victory Fund is citing the website Electful.com, which keeps track of candidates’ positions on issues, as the source for Doherty’s support for DOMA. On the other hand, Cicilline is an original co-sponsor of DOMA repeal legislation known as the Respect for Marriage Act.
The Democratic primary produced mixed results in terms of electing candidates who support marriage equality. One lesbian candidate, Laura Pisaturo, narrowly lost her bid to unseat a Democratic lawmaker who opposes same-sex marriage.
Many incumbent Democrats who support marriage equality fended off challenges from candidates who oppose it. Among those incumbents were State Sen. Ryan Pearson, State Rep. Arthur Handy, State Rep. Greg Amore, State Rep. Joseph Almeida, and State House Majority Whip Patrick O’Neill.
But in primaries in which pro-marriage equality challengers were running against incumbent Democrats who oppose it, the pro-LGBT side only won a single primary. Democrat Adam Satchell, a teacher and proponent of marriage equality, beat an incumbent Democrat who opposes same-sex marriage, State Sen. Michael Pinga.
Still, the outcome means a net gain of one vote in the State Senate at a time when legislation to enact same-sex marriage in the Ocean State is expected to advance next year.
In a competitive primary in State Senate District 29, incumbent State Sen. Michael McCaffrey, an opponent of marriage equality, won against Pisaturo, who was endorsed by the Victory Fund. McCaffrey had a narrow win against Pisaturo, taking 53 percent of the vote compared to Pisaturo’s 47 percent.
McCaffrey, chairs Rhode Island’s Senate Judiciary Committee, and, even though he’s a Democrat, has never allowed pending same-sex marriage legislation to advance in his committee. During a TV debate last month, McCaffrey said he “believes that marriage is between a man and a woman.”
Ray Sullivan, campaign director of Marriage Equality Rhode Island, said his organization is “incredibly proud” of the campaign Pisaturo waged despite her loss.
“We’re proud to have been a part of it,” Sullivan added. “She talked about issues that were important to people in that district, and if we had it to do all over again, we would absolutely stand with her.”
Asked whether marriage equality legislation can still advance, Sullivan said he intends to take McCaffrey “at his word” when the Democrat said during an earlier debate he’ll allow a vote on same-sex legislation in his committee despite his opposition to same-sex marriage.
“When we win a number of these races in the general election and we elect a pro-equality majority in the Senate in the general election, we expect Sen. McCaffrey to honor that commitment, and we look forward to scheduling a committee vote on marriage equality in the Senate Judiciary Committee,” Sullivan said.
In an interview with Washington Blade last week during the Democratic National Convention, Rhode Island Gov. Lincoln Chafee, a supporter of marriage equality, said the election of Pisaturo would be “pivotal” in determining whether same-sex marriage legislation would be able to advance in the Rhode Island legislature.
Other Senate races had disappointing outcomes for marriage equality proponents. Same-sex marriage opponent State Sen. Marc Cote won his primary against challenger Lewis Pryeor, who supports same-sex marriage. Similarly, marriage equality opponent State Sen. Daniel DaPonte won over challenger and marriage equality supporter Roberto DaSilva.
One race in which there was no incumbent also yielded a loss for marriage equality supporters. In State Senate District 26, Gene Dyszlewski, who supports marriage equality, lost to Frank Lombardi, who opposes same-sex marriage.
In State Senate District 33, David Gorman, a Democratic supporter of marriage equality, lost to Leonidas Raptakis, a Democratic opponent of gay nuptials. But the result in that race is a wash in that district because the incumbent Republican, State Sen. Glenford Shibley, opposes marriage equality.
According to WPRI, a group known as People for Rhode Island’s Future spent $26,500 earlier this month to elect six pro-marriage equality candidates in the Democratic primary. That group reportedly received a $20,000 donation to make that happen from Tim Gill, a gay Denver-based entrepreneur and philanthropist known for working to advance marriage equality, as well as $15,000 from Esmond Harmsworth, a Newport, R.I., resident and founding partner of Boston literary agency Zachary Shuster Harmsworth Literary Agency.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
